CHAMP: Study of NVK-002 in Children With Myopia



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:3 - 17
Updated:11/3/2018
Start Date:November 20, 2017
End Date:November 2022
Contact:Scott Smith
Email:scott.smith@syneoshealth.com
Phone:919-745-2461

Use our guide to learn which trials are right for you!

A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia

Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to
Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment
period.

Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of
treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive
myopia.

This will be a 3-arm randomized, multicenter, double-masked, placebo-controlled study
conducted in 2 stages.

Stage 1 is a safety and efficacy phase of 3 years in duration, during which subjects will be
allocated to 1 of 3 study medications.

Stage 2 is a randomized cross-over phase of 1 year in duration, during which subjects will be
re-randomized to receive 1 of the 3 study medications, with subjects initially randomized to
Vehicle only eligible for randomization to low or high-dose NVK-002.

Treatment arms are:

- NVK-002 low dose concentration

- NVK-002 high dose concentration

- Vehicle (placebo)

Inclusion Criteria:

1. Children aged 3 to ≤ 17.0 years.

2. Myopia SER of at least -0.50 D and no greater than -6.00 D myopia in each eye as
measured by cycloplegic autorefraction.

Exclusion Criteria:

1. If present, astigmatism more than -1.50 D in either eye.

2. Current or history of amblyopia or strabismus.

3. History of any disease or syndrome that predisposes the subject to severe myopia
(e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity).

4. History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus,
lenticonus, spherophakia).

5. Serious systemic illness that, in the Investigator's opinion, would render the subject
ineligible.

6. Chronic use (more than 3 days per week) of any topical ophthalmic medications
(prescribed or over the-counter) other than the assigned study medication.
We found this trial at
17
sites
?
mi
from
Maitland, FL
Click here to add this to my saved trials
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Danbury, CT
Click here to add this to my saved trials
?
mi
from
Elkins Park, PA
Click here to add this to my saved trials
?
mi
from
Forest Grove, OR
Click here to add this to my saved trials
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
?
mi
from
Kirkland, WA
Click here to add this to my saved trials
?
mi
from
Lancaster, PA
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials